While BTK inhibitors are emerging drugs that promote apoptosis in DLBCL [36], the BCR signal suppression in CD5-positive DLBCL may make these cells resistant to BTK inhibitors. The gene discussed is CD5; the disease is diffuse large B-cell lymphoma.